Hatch-Waxman Act
The 1984 U.S. law that streamlined generic drug approval by letting generics rely on the brand's safety/efficacy data and rewarding the first generic patent challenger with exclusivity.
As defined in Robin Feldman on Drug Patents, Generics, and Drug Wars
Where it comes up · 3
- Robin Feldman on Drug Patents, Generics, and Drug Wars5 claims
- What Makes a Quality Company1 claim
- Richard Epstein on Property Rights and Drug Patents 2/19/20071 claim
Most important claims · 7 of 7Search all claims for “Hatch-Waxman Act” →
- Prior to the 1984 Hatch-Waxman Act, only about 13% of prescriptions in the United States were filled by generics; today that figure is 80-90%, demonstrating the Act's dramatic effect on generic adoption.Robin Feldman on Drug Patents, Generics, and Drug Wars
- Hatch-Waxman's key reform allowed generic companies to rely on the brand-name drug's already-proven safety and efficacy: the brand must show the drug is safe and works, but the generic only has to show bioequivalence—that its product is the same as the approved drug—avoiding the absurdity of repeating years of clinical trials on an identical chemical.Robin Feldman on Drug Patents, Generics, and Drug Wars
- To entice generics into costly patent battles, Hatch-Waxman grants the first generic to successfully challenge a patent six months of marketing exclusivity—effectively a duopoly with only the brand and that one generic on the market—after which all other generics may enter.Robin Feldman on Drug Patents, Generics, and Drug Wars
- The Hatch-Waxman Act of 1984 restores patent term for FDA review time, roughly one day for every two days spent in regulatory process up to a cap, but the restoration becomes less effective the longer review drags on, so effective market life has shrunk to about 8-9 years for many drugs.Richard Epstein on Property Rights and Drug Patents 2/19/2007
- The core problem of the Hatch-Waxman system is its complexity: every elaborate rule built to introduce generics creates new opportunities to manipulate it, and as Congress tinkers with patches to stop exploitation it only adds more complexity and new loopholes, so the same battle is fought without gaining ground—'death by tinkering.'Robin Feldman on Drug Patents, Generics, and Drug Wars
- On balance Hatch-Waxman is half-full and even miraculous in moving the United States toward a system of generic drugs, but the real challenge—and the looming question—is whether it can continue to survive as new waves of game-playing unfold.Robin Feldman on Drug Patents, Generics, and Drug Wars
- Bloomstran owned Mylan several times on the thematic thesis of a generic-drug opportunity created by the patent cliff under Hatch-Waxman, but the firm's suspect accounting, revolving CFOs, and high executive pay led him to conclude it lacked business quality and to walk away after making money.What Makes a Quality Company